Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. - Wikidata - wikimedia - TriplyDB

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

http://www.wikidata.org/entity/Q33397018

about

Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors Management of patients with hepatic metastases from neuroendocrine tumors Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotate Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy.Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies.A novel statistical analysis method to improve the detection of hepatic foci of (111)In-octreotide in SPECT/CT imaging.Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.IMPROVED PLANAR KIDNEY ACTIVITY CONCENTRATION ESTIMATE BY THE POSTERIOR VIEW METHOD IN 177LU-DOTATATE TREATMENTS.Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocr Evaluation of two intraoperative gamma detectors for assessment of 177Lu activity concentration in vivo.Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1 The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature Lutetium-labelled peptides for therapy of neuroendocrine tumours.The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.Therapeutic strategies for neuroendocrine liver metastases.Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy.Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life (177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model.Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.

P2860

Q26783272-44002A34-49E0-4F2B-ABBC-579D3EE30948 Q27008832-F217C4FD-D4FE-48A4-ACB0-4760800F9030 Q28071978-3DC5D306-B2BD-40BA-AD6D-9A0DBB017124 Q33403035-652D0258-5D20-44BB-B79A-FD533B77BD01 Q33435622-82CAF5A1-A7DA-4716-94CC-E716E398F909 Q33438326-58A3D475-8ADA-4DC8-90B0-B2C32081C998 Q33737587-2D5B423D-9DDF-4F11-AAA5-925E8B889161 Q34157391-B3748EBA-A75C-4318-9E7D-F550CE4BD640 Q35244181-932F4864-59E6-49A1-B7AB-5D0C382AA03A Q35402008-F78B081F-79DF-4CEB-A10D-03ECEA8BE284 Q35675510-057C5AFA-C347-49F7-86B8-2FC9719981DE Q35724907-E6EA2CD5-D7AA-48EC-AFCA-99AA1AE9A516 Q35738251-5530EDE0-9DDF-4F71-9CFD-04EC1038EDA7 Q35941125-CD91F871-65BE-428B-AC7B-4A04ADB3D4D8 Q36011116-B194D5E7-0DA4-4ADE-A047-DC5260C247B7 Q36265194-F4BFB26C-AE97-4E7C-89C3-BAAADB8E3DE8 Q36480036-34B77B17-C426-4FAB-8141-71611E7DA5D3 Q36516035-DCE9A84D-12F0-4F71-B42A-3369B0F8C6FC Q36578624-74E1AD0D-8BF7-4AD3-9BD2-244E732F15B5 Q36644325-729CC44F-EBAD-468B-B2D8-4140A2A9ACBD Q36942728-190E9EFF-1A71-4E72-A02F-79180D6D11B7 Q37016021-F2898195-38E1-4AE5-98E7-24B3837659A5 Q37143853-8CB97A92-9A72-4AF9-9F23-70C9E111171D Q37156083-18A8E049-4421-439F-BB6D-A0376E818656 Q37164623-43DC0FF5-1CCE-457D-94B8-FB32574BAD8D Q37273187-B84805E8-98AF-45EE-B54F-BF9512E7D6E7 Q37425156-8CD67194-4981-4DA6-AD56-B9BEBFEE9E6D Q37574732-935E984E-C4DE-437D-8906-72DAF6471676 Q37590508-6AEB20C3-1AAD-4E53-900B-C35EAABC5BA8 Q37646677-082D51BE-29A9-4E32-B797-C674B5870953 Q37990411-66963699-09A7-4BA5-9740-753CA13BDFC4 Q38219225-0297090C-A38D-4D28-A3A8-5F19F3A10E37 Q38255979-6D66A547-A04D-4937-99E3-964B8F466434 Q38271733-5C74CDC7-8FBF-47A1-A033-8F2EC632D79F Q38469898-57748D3E-E997-44FA-8292-71DFD1B6A5AC Q38625614-3C41BF7E-31EE-47A6-AA19-C36AB258980F Q38756968-165BFB72-4E3F-4279-93E1-A67392236E58 Q38853973-82226903-FF3B-4A38-9407-A6A48BBE94B0 Q38870046-7751711E-70D8-457A-9D99-77E8627305F9 Q38884776-B7043D8D-5DF5-4A6C-A5FC-C0EFD4E849DF

P2860

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

http://www.wikidata.org/entity/Q33397018

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

@ast

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

@en

type

label

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

@ast

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

@en

prefLabel

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

@ast

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

@en

P1433

Q33397018-90E0B813-34FB-48CA-BC4D-C39839746257

P1476

Q33397018-B87541DE-5E01-4F0D-AC57-29B89E4C1E23

P2093

Q33397018-084C025E-464E-427B-925E-2F30330711DC

Q33397018-1363ABA3-4488-4B21-8F8A-3A595C3964C7

Q33397018-38E8FDB5-5E43-445B-903F-05B675E2FD5C

Q33397018-56CFF8D1-AA08-4550-8604-7C1D9C00113A

Q33397018-7B604119-96BD-4AB8-98B0-2632C8CCFBE1

Q33397018-8550F16A-C99A-4264-85A5-11CDA038791D

Q33397018-9A11EC6D-3059-4691-B596-B6467C8C43DA

Q33397018-D618D7C7-BCD8-44F0-8B2D-02DE7FD1B826

Q33397018-DCBDC4AC-0ADF-42E7-A6B7-629711EF3A7A

Q33397018-E4044F59-F74E-4700-A84B-C89BE9821ACE

P2860

Q33397018-03BCDAFF-2A6E-4934-BBA9-7FADBFBFB6B3

Q33397018-1232B74A-F7B0-439A-BC3B-66F4E64014AC

Q33397018-15F789F8-35AF-42F7-B0CD-6C14EBF8E664

Q33397018-170606B0-1721-4393-89E5-AEE4D4804EB2

Q33397018-2705F6C3-7E5E-477A-985D-E8BFD6180C71

Q33397018-2CBDEA26-848D-468C-A6F6-540E9F8A3330

Q33397018-318D7412-ABC6-4297-8847-882D94100EF2

Q33397018-4E5FD1BE-3151-42FA-B98F-1F14F529434E

Q33397018-5570F503-23A5-4ECB-B290-78DD26B8B728

Q33397018-5A878115-DA0D-40EC-B80C-8DCB549374F8

P2888

Q33397018-A2150A8C-E209-4EAC-B1E1-7F5379F8AAD2

P304

Q33397018-509F4804-07FB-4443-B4EE-81EBEFC55ADE

P31

Q33397018-6529225F-D0D0-4B85-ACCF-A18639D7E5AA

P356

Q33397018-D46DC0D5-95A2-4BB1-921A-2C7F256FA669

P433

Q33397018-DE44C7CE-0935-4080-8E6E-67BEB7889302

P478

Q33397018-E64B4A82-47D6-4313-B977-B866C242D923

P50

Q33397018-1C683755-8379-4809-A831-89D3A94CFFD4

Q33397018-49E52613-AA0C-4BA7-B79D-B64C24A8AC05

P577

Q33397018-80375226-3BD8-47F6-8616-6CBF642690B4

P698

Q33397018-A58CF7C8-EBFE-42DD-B9F9-75E753413CBF

P356

S00259-011-1902-1

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

@en

P2093

Chiara M Grana

http://www.w3.org/2001/XMLSchema#string

Dario Lombardo

http://www.w3.org/2001/XMLSchema#string

Lisa Bodei

http://www.w3.org/2001/XMLSchema#string

Maddalena Sansovini

http://www.w3.org/2001/XMLSchema#string

Mahila E Ferrari

http://www.w3.org/2001/XMLSchema#string

Marco Chinol

http://www.w3.org/2001/XMLSchema#string

Marta Cremonesi

http://www.w3.org/2001/XMLSchema#string

Mirco Bartolomei

http://www.w3.org/2001/XMLSchema#string

Silvia M Baio

http://www.w3.org/2001/XMLSchema#string

Simona Iodice

http://www.w3.org/2001/XMLSchema#string

P2860

Gastroenteropancreatic neuroendocrine tumours

Prediction of creatinine clearance from serum creatinine

Anemia of chronic disease.

Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy.

Introduction to clinical radiation biology.

Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal.

Peptide receptor therapies in neuroendocrine tumors.

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

P2888

s00259-011-1902-1

P304

2125-2135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-011-1902-1

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Paganelli

P577

2011-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21892623

http://www.w3.org/2001/XMLSchema#string